Legal & General Group PLC Verve Therapeutics, Inc. Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 55,827 shares of VERV stock, worth $251,221. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,827
Previous 55,827 -0.0%
Holding current value
$251,221
Previous $270,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$4.76 - $12.79 $9,391 - $25,234
1,973 Added 3.66%
55,827 $272,000
Q1 2024

May 14, 2024
BUY
$10.81 - $17.96 $22,960 - $38,147
2,124 Added 4.11%
53,854 $715,000
Q4 2023

Feb 15, 2024
BUY
$8.84 - $18.7 $113,859 - $240,856
12,880 Added 33.15%
51,730 $721,000
Q3 2023

Nov 14, 2023
BUY
$11.42 - $20.82 $58,527 - $106,702
5,125 Added 15.2%
38,850 $515,000
Q2 2023

Aug 14, 2023
BUY
$13.34 - $19.9 $262,010 - $390,855
19,641 Added 139.46%
33,725 $632,000
Q1 2023

May 15, 2023
BUY
$14.3 - $24.01 $11,640 - $19,544
814 Added 6.13%
14,084 $203,000
Q4 2022

Feb 14, 2023
BUY
$17.85 - $40.7 $10,120 - $23,076
567 Added 4.46%
13,270 $256,000
Q3 2022

Nov 14, 2022
BUY
$15.63 - $41.49 $76,868 - $204,047
4,918 Added 63.17%
12,703 $437,000
Q2 2022

Aug 22, 2022
BUY
$11.14 - $23.17 $2,807 - $5,838
252 Added 3.35%
7,785 $119,000
Q1 2022

May 16, 2022
BUY
$20.92 - $39.36 $41,693 - $78,444
1,993 Added 35.97%
7,533 $172,000
Q4 2021

Feb 14, 2022
BUY
$31.94 - $54.82 $129,484 - $222,240
4,054 Added 272.81%
5,540 $204,000
Q3 2021

Nov 15, 2021
BUY
$46.0 - $73.99 $68,356 - $109,949
1,486 New
1,486 $70,000

Others Institutions Holding VERV

# of Institutions
186
Shares Held
73.3M
Call Options Held
85K
Put Options Held
215K
View Full List

About Verve Therapeutics, Inc.

VERV Quotes by TradingView
  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $270M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email